{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T19:39:52Z","timestamp":1781033992653,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd001901.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2020,6,30]],"date-time":"2020-06-30T00:00:00Z","timestamp":1593475200000}}],"reference-count":72,"publisher":"Wiley","issue":"6","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd001901.pub3","type":"journal-article","created":{"date-parts":[[2020,7,6]],"date-time":"2020-07-06T08:16:36Z","timestamp":1594023396000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Levetiracetam add-on for drug-resistant focal epilepsy"],"prefix":"10.1002","volume":"2020","author":[{"given":"Gashirai K","family":"Mbizvo","sequence":"additional","affiliation":[{"name":"The Walton Centre NHS Foundation Trust; Liverpool UK"},{"name":"Muir Maxwell Epilepsy Centre, Centre for Clinical Brain Sciences, University of Edinburgh; Edinburgh UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bharath","family":"Chandrasekar","sequence":"additional","affiliation":[{"name":"University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah J","family":"Nevitt","sequence":"additional","affiliation":[{"name":"Department of Biostatistics; University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pete","family":"Dixon","sequence":"additional","affiliation":[{"name":"Department of Molecular and Clinical Pharmacology; Institute of Translational Medicine, University of Liverpool; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane L","family":"Hutton","sequence":"additional","affiliation":[{"name":"Department of Statistics; University of Warwick; Coventry UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony G","family":"Marson","sequence":"additional","affiliation":[{"name":"The Walton Centre NHS Foundation Trust; Liverpool UK"},{"name":"Department of Molecular and Clinical Pharmacology; Institute of Translational Medicine, University of Liverpool; Liverpool UK"},{"name":"Liverpool Health Partners; Liverpool UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,6,30]]},"reference":[{"issue":"10","key":"10.1002\/14651858.CD001901.pub3-BIB0001|cit1","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000 mg\/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European Levetiracetam Study Group","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0002|cit2","unstructured":"Evaluation of the efficacy and tolerability of UCB L059 (1500 mg b.i.d., 500 mg tablets) monotherapy in epileptic patients with complex partial onset seizures, having experienced improved seizure control under add-on treatment: a 60-week (maximum), double-blind, multicenter, responder-selected trial (phase III study, placebo comparator) UCB S.A. Pharma Sector"},{"issue":"2","key":"10.1002\/14651858.CD001901.pub3-BIB0003|cit3","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1053\/seiz.2000.0380","article-title":"A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy","volume":"9","author":"Betts","year":"2000","journal-title":"Seizure"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0004|cit4","unstructured":"A 24-week multicentered, double-blind, parallel group, add-on study to compare the efficacy and the tolerability of 2 oral daily doses of UCB L059 (2000 mg and 4000 mg tablets) with placebo in patients with refractory epilepsy, followed by a 24-week open-label active treatment UCB S.A. Pharma Sector"},{"issue":"2","key":"10.1002\/14651858.CD001901.pub3-BIB0005|cit5","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1212\/wnl.55.2.236","article-title":"Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"issue":"7","key":"10.1002\/14651858.CD001901.pub3-BIB0006|cit6","doi-asserted-by":"publisher","first-page":"868","DOI":"10.1111\/j.1528-1157.2000.tb00255.x","article-title":"Effect of levetiracetam on epilepsy-related quality of life: N132 study group","volume":"41","author":"Cramer","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0007|cit7","unstructured":"Evaluation of the efficacy and tolerability of UCB L059 (500 and 1500 mg bid, tablets) add-on treatment in epileptic patients with partial onset seizures: a 38-week, double-blind, placebo-controlled, parallel-group multicenter trial UCB S.A. Pharma Sector"},{"issue":"11","key":"10.1002\/14651858.CD001901.pub3-BIB0008|cit8","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1212\/01.wnl.0000217916.00225.3a","article-title":"Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures","volume":"66","author":"Glauser","year":"2006","journal-title":"Neurology"},{"issue":"10","key":"10.1002\/14651858.CD001901.pub3-BIB0009|cit9","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1111\/pcn.12300","article-title":"Efficacy and tolerability of levetiracetam as adjunctive therapy in Japanese patients with uncontrolled partial-onset seizures","volume":"69","author":"Inoue","year":"2015","journal-title":"Psychiatry and Clinical Neurosciences"},{"issue":"8","key":"10.1002\/14651858.CD001901.pub3-BIB0010|cit10","first-page":"787","article-title":"Adjunctive therapy of levetiracetam in adult Japanese patients with uncontrolled partial-onset seizures: pooled data from two double-blind, placebo-controlled, randomized trials","volume":"36","author":"Yamada","year":"2015","journal-title":"Therapeutic Research"},{"issue":"11","key":"10.1002\/14651858.CD001901.pub3-BIB0011|cit11","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1111\/j.1528-1167.2009.02197.x","article-title":"Neurocognitive effects of adjunctive levetiracetam in children with partial-onset seizures: a randomized, double-blind, placebo-controlled, noninferiority trial","volume":"50","author":"Levisohn","year":"2009","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD001901.pub3-BIB0012|cit12","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/j.yebeh.2010.04.017","article-title":"Assessment of behavioral and emotional functioning using standardized instruments in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial","volume":"18","author":"la Loge","year":"2010","journal-title":"Epilepsy & Behavior"},{"issue":"3","key":"10.1002\/14651858.CD001901.pub3-BIB0013|cit13","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1111\/j.1528-1167.2008.01817.x","article-title":"Once-daily extended-release levetiracetam as adjunctive treatment of partial-onset seizures in patients with epilepsy: a double-blind, randomized, placebo-controlled trial","volume":"50","author":"Peltola","year":"2009","journal-title":"Epilepsia"},{"issue":"9","key":"10.1002\/14651858.CD001901.pub3-BIB0014|cit14","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1111\/j.1528-1157.2000.tb00323.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures","volume":"41","author":"Shorvon","year":"2000","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0015|cit15","unstructured":"Evaluation of the efficacy and tolerability of UCB L059 (500 and 1000 mg b.i.d., tablets) add-on treatment in refractory epileptic patients with partial onset seizures: a 32-week double-blind placebo-controlled crossover multicenter trial UCB S.A. Pharma Sector"},{"issue":"1","key":"10.1002\/14651858.CD001901.pub3-BIB0016|cit16","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1111\/j.1528-1167.2006.00372.x","article-title":"Efficacy and safety of levetiracetam (up to 2000 mg\/day) in Taiwanese patients with refractory partial seizures: a multicenter, randomized, double-blind, placebo-controlled study","volume":"47","author":"Tsai","year":"2006","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD001901.pub3-BIB0017|cit17","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/j.1528-1167.2008.01729.x","article-title":"Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in Chinese patients with refractory partial-onset seizures","volume":"50","author":"Wu","year":"2009","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD001901.pub3-BIB0018|cit18","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000197109","article-title":"Efficacy and safety of levetiracetam (3,000 mg\/day) as an adjunctive therapy in Chinese patients with refractory partial seizures","volume":"61","author":"Xiao","year":"2009","journal-title":"European Neurology"},{"issue":"1","key":"10.1002\/14651858.CD001901.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"3","DOI":"10.3805\/jjes.28.3","article-title":"Multicenter, double-blind, randomized, placebo-controlled study of levetiracetam as add-on therapy in Japanese patients with uncontrolled partial seizures","volume":"28","author":"Yagi","year":"2010","journal-title":"Journal of the Japan Epilepsy Society"},{"issue":"8","key":"10.1002\/14651858.CD001901.pub3-BIB0020|cit20","first-page":"787","article-title":"Adjunctive therapy of levetiracetam in adult Japanese patients with uncontrolled partial-onset seizures: pooled data from two double-blind, placebo-controlled, randomized trials","volume":"36","author":"Yamada","year":"2015","journal-title":"Therapeutic Research"},{"issue":"2","key":"10.1002\/14651858.CD001901.pub3-BIB0021|cit21","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3969\/j.issn.1672-6731.2009.02.016","article-title":"Study on the therapeutic effect of levetiracetam as an additive therapy for refractory partial epilepsy and the relativity between levetiracetam and multidrug resistance gene: a randomised double-blind placebo-controlled trial","volume":"9","author":"Zheng","year":"2009","journal-title":"Chinese Journal of Contemporary Neurology and Neurosurgery"},{"issue":"2","key":"10.1002\/14651858.CD001901.pub3-BIB0022|cit22","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.yebeh.2007.10.003","article-title":"Effects of levetiracetam as an add-on therapy on cognitive function and quality of life in patients with refractory partial seizures","volume":"12","author":"Zhou","year":"2008","journal-title":"Epilepsy & Behavior"},{"issue":"1","key":"10.1002\/14651858.CD001901.pub3-BIB0023|cit23","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S0920-1211(01)00323-0","article-title":"Dose-response effect of levetiracetam 1000 and 2000mg\/day in partial epilepsy","volume":"48","author":"Boon","year":"2002","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0024|cit24","unstructured":"Efficacy and safety of levetiracetam in partial seizures control, with or without secondary generalization (Mozart) clinicaltrials.gov\/ct2\/show\/NCT01392768"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0025|cit25","first-page":"299. Abstract n","article-title":"Behavioral changes associated with levetiracetam use in patients with epilepsy","volume":"42 (Suppl 7)","author":"Asconap\u00e9","year":"2001","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD001901.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1111\/j.1528-1167.2010.02522.x","article-title":"Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on Classification and Terminology, 2005-2009","volume":"51","author":"Berg","year":"2010","journal-title":"Epilepsia\u00a0"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0027|cit27","volume-title":"British National Formulary","author":"Joint Formulary Committee","year":"2019"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0028|cit28","volume-title":"British National Formulary for Children","author":"Joint Formulary Committee","year":"2019"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0029|cit29","doi-asserted-by":"crossref","unstructured":"Brodie MJ Antiepileptic drug therapy the story so far Seizure 2010 19 10 650 5","DOI":"10.1016\/j.seizure.2010.10.027"},{"issue":"6","key":"10.1002\/14651858.CD001901.pub3-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1016\/S1525-5050(02)00531-0","article-title":"Magnitude of the placebo effect in randomized trials of antiepileptic agents","volume":"3","author":"Burneo","year":"2002","journal-title":"Epilepsy & Behavior"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.yebeh.2017.08.039","article-title":"Psychiatric and behavioral side effects of antiepileptic drugs in adults with epilepsy","volume":"76","author":"Chen","year":"2017","journal-title":"Epilepsy & Behavior"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/NDT.S188111","article-title":"A meta-analysis of levetiracetam for randomized placebo-controlled trials in patients with refractory epilepsy","volume":"15","author":"Chen","year":"2019","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"10","key":"10.1002\/14651858.CD001901.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1111\/j.1528-1157.1998.tb01295.x","article-title":"Neuropsychological outcomes in randomized controlled trials of antiepileptic drugs: a systematic review of methodology and reporting standards","volume":"39","author":"Cochrane","year":"1998","journal-title":"Epilepsia"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD001901.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1528-1167.2011.03237.x","article-title":"Established Status Epilepticus Treatment Trial (ESETT)","volume":"52","author":"Cock","year":"2011","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2147\/DDDT.S103468","article-title":"New developments in the management of partial-onset epilepsy: role of brivaracetam","volume":"11","author":"Coppola","year":"2017","journal-title":"Drug design, development and therapy"},{"issue":"2","key":"10.1002\/14651858.CD001901.pub3-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1586\/ern.10.3","article-title":"Levetiracetam: a comprehensive review","volume":"10","author":"Crepeau","year":"2010","journal-title":"Expert Review of Neurotherapeutics"},{"issue":"2","key":"10.1002\/14651858.CD001901.pub3-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/WCO.0000000000000174","article-title":"Redefining epilepsy","volume":"28","author":"Fisher","year":"2015","journal-title":"Current Opinion in Neurology"},{"issue":"4","key":"10.1002\/14651858.CD001901.pub3-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"issue":"4","key":"10.1002\/14651858.CD001901.pub3-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/epi.13671","article-title":"Instruction manual for the ILAE 2017 operational classification of seizure types","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"issue":"1","key":"10.1002\/14651858.CD001901.pub3-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/NDT.S1655","article-title":"Monotherapy for partial epilepsy: focus on levetiracetam","volume":"4","author":"Gambardella","year":"2008","journal-title":"Neuropsychiatric Disease and Treatment"},{"issue":"3","key":"10.1002\/14651858.CD001901.pub3-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1528-1167.2006.00454.x","article-title":"Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus","volume":"47","author":"Gibbs","year":"2006","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0042|cit42","doi-asserted-by":"crossref","unstructured":"Gillard M Chatelain P Fuks B Binding characteristics of levetiracetam to synaptic vesicle protein 2A (SV2A) in human brain and in CHO cells expressing the human recombinant protein European Journal of Pharmacology 2006 536 1-2 102 8","DOI":"10.1016\/j.ejphar.2006.02.022"},{"issue":"1","key":"10.1002\/14651858.CD001901.pub3-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.yebeh.2009.10.007","article-title":"Placebo responses in randomized trials of antiepileptic drugs","volume":"17","author":"Guekht","year":"2010","journal-title":"Epilepsy & Behavior"},{"issue":"9","key":"10.1002\/14651858.CD001901.pub3-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.seizure.2014.06.004","article-title":"Behavioral side-effects of levetiracetam in children with epilepsy: a systematic review","volume":"23","author":"Halma","year":"2014","journal-title":"Seizure"},{"issue":"5","key":"10.1002\/14651858.CD001901.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2176\/nmc.ra.2015-0344","article-title":"The new antiepileptic drugs: their neuropharmacology and clinical indications","volume":"56","author":"Hanaya","year":"2016","journal-title":"Neurologia Medico-chirurgica"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0046|cit46","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions 4.2.4 (updated March 2005)","author":"Higgins","year":"2005"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0047|cit47","unstructured":"Higgins JP Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"10","key":"10.1002\/14651858.CD001901.pub3-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.seizure.2011.07.007","article-title":"The impact of epilepsy on children and adult patients' lives: development of a conceptual model from qualitative literature","volume":"20","author":"Kerr","year":"2011","journal-title":"Seizure"},{"issue":"6","key":"10.1002\/14651858.CD001901.pub3-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0050|cit50","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0051|cit51","doi-asserted-by":"crossref","unstructured":"Lukyanetz EA Shkryl VM Kostyuk PG Selective blockade of N-type calcium channels by levetiracetam Epilepsia 2002 43 1 9 18","DOI":"10.1046\/j.1528-1157.2002.24501.x"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0052|cit52","doi-asserted-by":"crossref","unstructured":"Lynch BA Lambeng N Nocka K Kensel-Hammes P Bajjalieh SM Matagne A The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam Proceedings of the National Academy of Sciences of the United States of America 2004 101 26 9861 6","DOI":"10.1073\/pnas.0308208101"},{"issue":"4","key":"10.1002\/14651858.CD001901.pub3-BIB0053|cit53","first-page":"489","article-title":"Levetiracetam: a review of its use in epilepsy","volume":"71","author":"Lyseng-Williamson","year":"2011","journal-title":"Drugs"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0054|cit54","unstructured":"Maguire M Marson AG Ramaratnam S Epilepsy (partial) BMJ Clinical Evidence 2011 2011 1214 21549021"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001901.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"S111","DOI":"10.1016\/S1388-2457(00)00410-7","article-title":"Evaluation of sleepiness in epilepsy","volume":"111","author":"Manni","year":"2000","journal-title":"Clinical Neurophysiology"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0056|cit56","volume-title":"Methodological Expectations of Cochrane Intervention Reviews","author":"Higgins","year":"2012"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0057|cit57","unstructured":"National Institute for Health and Clinical Excellence The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care, January 2012 www.guidance.nice.org.uk\/CG137"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0058|cit58","doi-asserted-by":"crossref","unstructured":"Niespodziany I Klitgaard H Margineanu DG Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurones of rat hippocampal slices Neuroscience Letters 2001 306 1-2 5 8","DOI":"10.1016\/S0304-3940(01)01884-5"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0059|cit59","doi-asserted-by":"crossref","unstructured":"Pellock JM Glauser TA Bebin EM Fountain NB Ritter FJ Coupez RM Pharmacokinetic study of levetiracetam in children Epilepsia 2001 42 12 1574 9","DOI":"10.1046\/j.1528-1157.2001.41300.x"},{"issue":"4","key":"10.1002\/14651858.CD001901.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1535-7597.2004.44009.x","article-title":"Much ado about something or nothing: behavioral problems with levetiracetam use in epilepsy patients","volume":"4","author":"Penovich","year":"2004","journal-title":"Epilepsy Currents \/ American Epilepsy Society"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0061|cit61","doi-asserted-by":"crossref","unstructured":"Rigo JM Hans G Nguyen L Rocher V Belachew S Malgrange B The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents British Journal of Pharmacology 2002 136 5 659 72","DOI":"10.1038\/sj.bjp.0704766"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0062|cit62","unstructured":"A pragmatic randomised controlled trial comparing the effectiveness and cost effectiveness of levetiracetam and zonisamide versus standard treatments for epilepsy: a comparison of Standard And New Antiepileptic Drugs (SANAD-II) www.sanad2.org.uk\/"},{"issue":"4","key":"10.1002\/14651858.CD001901.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0064|cit64","unstructured":"Sch\u00fcnemann H Bro\u017cek J Oxman A GRADE handbook for grading quality of evidence and strength of recommendation. Version 3.2 (updated March 2009). The GRADE Working Group, 2009 Available from www.cc-ims.net\/gradepro"},{"issue":"Suppl 2","key":"10.1002\/14651858.CD001901.pub3-BIB0065|cit65","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1111\/j.1528-1157.1996.tb06027.x","article-title":"The epidemiology and treatment of chronic and refractory epilepsy","volume":"37","author":"Shorvon","year":"1996","journal-title":"Epilepsia"},{"issue":"3","key":"10.1002\/14651858.CD001901.pub3-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.eplepsyres.2006.11.006","article-title":"Dose-response population analysis of levetiracetam add-on treatment in refractory epileptic patients with partial onset seizures","volume":"73","author":"Snoeck","year":"2007","journal-title":"Epilepsy Research"},{"key":"10.1002\/14651858.CD001901.pub3-BIB0067|cit67","unstructured":"Stata StataCorp 2015"},{"issue":"7","key":"10.1002\/14651858.CD001901.pub3-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/epi.13021","article-title":"Valproate in the treatment of epilepsy in girls and women of childbearing potential","volume":"56","author":"Tomson","year":"2015","journal-title":"Epilepsia"},{"issue":"Suppl 8","key":"10.1002\/14651858.CD001901.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1528-1167.2011.03232.x","article-title":"What is the evidence to use new intravenous AEDs in status epilepticus?","volume":"52","author":"Trinka","year":"2011","journal-title":"Epilepsia"},{"issue":"24","key":"10.1002\/14651858.CD001901.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"3417","DOI":"10.1002\/1097-0258(20001230)19:24<3417::AID-SIM614>3.0.CO;2-L","article-title":"A multilevel model framework for meta-analysis of clinical trials with binary outcomes","volume":"19","author":"Turner","year":"2000","journal-title":"Statistics in Medicine"},{"issue":"1","key":"10.1002\/14651858.CD001901.pub3-BIB0071|cit71","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001901","article-title":"Levetiracetam add-on for drug-resistant localization related (partial) epilepsy","author":"Chaisewikul","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD001901.pub3-BIB0072|cit72","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001901.pub2","article-title":"Levetiracetam add-on for drug-resistant focal epilepsy: an updated Cochrane Review","author":"Mbizvo","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,1,25]],"date-time":"2023-01-25T09:03:39Z","timestamp":1674637419000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD001901.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Epilepsy Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,6,30]]},"references-count":72,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd001901.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,30]]}}}